Herpes simplex virus drug-resistance: New mutations and insights

Current Opinion in Infectious Diseases

Volumn 26, Issue 6, 2013, Pages 551-560

  Andrei, Graciela ^a   Snoeck, Robert ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

acyclovir resistance; herpes simplex encephalitis; herpes simplex virus; herpetic keratitis; phenotyping genotyping

Indexed keywords

ACICLOVIR; ACICLOVIR TRIPHOSPHATE; AIC 316; AMENAMEVIR; BAY 57 1293; CIDOFOVIR; DEFENSIN; DNA PRIMASE; FAMCICLOVIR; FOSCARNET; FOSCARNET SODIUM; HELICASE; IMIQUIMOD; PENCICLOVIR; PENCICLOVIR TRIPHOSPHATE; PRITELIVIR; UNCLASSIFIED DRUG; VALACICLOVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL PROTOCOL; CONDYLOMA ACUMINATUM; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HERPES SIMPLEX; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOCOMPETENCE; IMMUNOCOMPETENT PATIENT; IMMUNOCOMPROMISED PATIENT; NEPHROTOXICITY; NONHUMAN; PHENOTYPE; REVIEW; VIRUS EXAMINATION; VIRUS IDENTIFICATION; VIRUS MUTATION; VIRUS STRAIN; VIRUS TYPING;

ACYCLOVIR; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HERPES SIMPLEX; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST;

EID: 84887316810     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000015     Document Type: Review

References (62)

1. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet 2001; 357:1513-1518.
2. Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001; 108:223-229.
3. James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res 2009; 83:207-213.
4. Mailles A, Stahl JP. Infectious encephalitis in France in 2007: a national prospective study. Clin Infect Dis 2009; 49:1838-1847.
5. Stahl JP, Mailles A, De Broucker T. Herpes simplex encephalitis and management of acyclovir in encephalitis patients in France. Epidemiol Infect 2012; 140:372-381.
6. Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, populationbased prospective study. Lancet Infect Dis 2010; 10:835-844.
7. Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? Curr Opin Neurol 2011; 24:268-274.
8. Revere K, Davidson SL. Update on management of herpes keratitis in children. Curr Opin Ophthalmol 2013; 24:343-347.
9. Vere Hodge RA, Field HJ. Antiviral agents for herpes simplex virus. Adv Pharmacol 2013; 67:1-38.
10. EarnshawDL, BaconTH, Darlison SJ, et al.Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother 1992; 36:2747-2757.
11. Sarisky RT, Quail MR, Clark PE, et al. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 2001; 75:1761-1769.
12. Andrei G, Fiten P, Froeyen M, et al. DNA polymerase mutations in drugresistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther 2007; 12:719-732.
13. Bacon TH, Levin MJ, Leary JJ, et al. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003; 16:114-128.
14. Sarisky RT, Bacon TH, Boon RJ, et al. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials. Arch Virol 2003; 148:1757-1769.
15. Safrin S, Phan L. In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 1993; 37:2241-2243.
16. Pardeiro M, Cuenca-Estrella M, Fernandez-Clua MA, et al. Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient. J Med Virol 2004; 73:60-64.
17. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Engl J Med 1991; 325:551-555.
18. Schulte EC, Sauerbrei A, Hoffmann D, et al. Acyclovir resistance in herpes simplex encephalitis. Ann Neurol 2010; 67:830-833.
19. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459-472.
20. Andrei G, Georgala A, Topalis D, et al. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. J Infect Dis 2013; 207:1295-1305.
21. Sauerbrei A, Bohn K, Heim A, et al. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther 2011; 16:1297-1308.
22. Blot N, Schneider P, Young P, et al. Treatment of an acyclovir and foscarnetresistant herpes simplex virus infection with cidofovir in a child after an unrelated bone marrow transplant. Bone Marrow Transplant 2000; 26:903-905.
23. Bryant P, Sasadeusz J, Carapetis J, et al. Successful treatment of foscarnetresistant herpes simplex stomatitis with intravenous cidofovir in a child. Pediatr Infect Dis J 2001; 20:1083-1086.
24. Lascaux AS, Caumes E, Deback C, et al. Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. J Med Virol 2012; 84:194-197.
25. Snoeck R, Andrei G, Gerard M, et al. Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 1994; 18:570-578.
26. Muluneh B, Dean A, Armistead P, Khan T. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. J Oncol Pharm Pract 2013; 19:181-185.
27. Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebocontrolled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997; 176:892-898.
28. Lalezari JP, Drew WL, Glutzer E, et al. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 1994; 170:570-572.
29. Snoeck R, Andrei G, De Clercq E, et al. A new topical treatment for resistant herpes simplex infections. N Engl J Med 1993; 329:968-969.
30. Stranska R, van Loon AM, Bredius RG, et al. Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child. Antivir Ther 2004; 9:97-104.
31. Gilbert J, Drehs MM, Weinberg JM. Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch Dermatol 2001; 137:1015-1017.
32. Martinez V, Molina JM, Scieux C, et al. Topical imiquimod for recurrent acyclovir-resistant HSV infection. Am J Med 2006; 119:e9-e11.
33. Perkins N, Nisbet M, Thomas M. Topical imiquimod treatment of aciclovirresistant herpes simplex disease: case series and literature review. Sex Transm Infect 2011; 87:292-295.
34. Bohn K, Zell R, Schacke M, et al. Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antivir Ther 2011; 16:989-997.
35. Karaba AH, Cohen LK, Glaubach T, et al. Longitudinal characterization of herpes simplex virus (HSV) isolates acquired from different sites in an immune-compromised child: a new HSV thymidine kinase mutation associated with resistance. J Pediatric Infect Dis Soc 2012; 1:116-124.
36. Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54:4833-4842.
37. Burrel S, Boutolleau D, Azar G, et al. Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis. J Clin Virol 2013; 58:321-324.
38. Sauerbrei A, Deinhardt S, Zell R, Wutzler P. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 2010; 86:246-252.
39. Stranska R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32:7-18.
40. Danve-Szatanek C, Aymard M, Thouvenot D, et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42:242-249.
41. Morfin F, Bilger K, Boucher A, et al. HSV excretion after bone marrow transplantation: a 4-year survey. J Clin Virol 2004; 30:341-345.
42. Shin YK, Cai GY, Weinberg A, et al. Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol 2001; 39:913-917.
43. Duan R, de Vries RD, van Dun JM, et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009; 200:1402-1414.
44. Duan R, de Vries RD, Osterhaus AD, et al. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008; 198:659-663.
45. Choong K, Walker NJ, Apel AJ, Whitby M. Aciclovir-resistant herpes keratitis. Clin Experiment Ophthalmol 2010; 38:309-313.
46. van Velzen M, van de Vijver DA, van Loenen FB, et al. Acyclovir prophylaxis predisposes to antiviral resistant recurrent herpetic keratitis. J Infect Dis 2013; 208:1359-1365.
47. van Velzen M, van Loenen FB, Meesters RJ, et al. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 2012; 205:1539-1543.
48. Gateley A, Gander RM, Johnson PC, et al. Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 1990; 161:711-715.
49. Pinninti SG, Angara R, Feja KN, et al. Neonatal herpes disease following maternal antenatal antiviral suppressive therapy: a multicenter case series. J Pediatr 2012; 161:134-138.
50. Kakiuchi S, Nonoyama S, Wakamatsu H, et al. Neonatal herpes encephalitis caused by a virologically confirmed acyclovir resistant herpes simplex virus type 1. J Clin Microbiol 2012; 51:356-359.
51. Oram RJ, Marcellino D, Strauss D, et al. Characterization of an acyclovirresistant herpes simplex virus type 2 strain isolated from a premature neonate. J Infect Dis 2000; 181:1458-1461.
52. Bache M, Andrei G, Bindl L, et al. Antiviral drug-resistance typing reveals compartmentalization and dynamics of acyclovir-resistant herpes simplex virus type-2 (HSV-2) in a case of neonatal herpes. J Pediatric Infect Dis So 2013. (in press).
53. Wang K, Mahalingam G, Hoover SE, et al. Diverse herpes simplex virus type 1 thymidine kinase mutants in individual human neurons and ganglia. J Virol 2007; 81:6817-6826.
54. Levin MJ, Weinberg A, Leary JJ, Sarisky RT. Development of acyclovirresistant herpes simplex virus early during the treatment of herpes neonatorum. Pediatr Infect Dis J 2001; 20:1094-1097.
55. Juhl D, Mosel C, Nawroth F, et al. Detection of herpes simplex virus DNA in plasma of patients with primary but not with recurrent infection: implications for transfusion medicine? Transfus Med 2010; 20:38-47.
56. Johnston C, Magaret A, Selke S, et al. Herpes simplex virus viremia during primary genital infection. J Infect Dis 2008; 198:31-34.
57. Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother 2010; 65:1733-1741.
58. Sukla S, Biswas S, Birkmann A, et al. Effects of therapy using a helicaseprimase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant. Antiviral Res 2010; 87:67-73.
59. Field HJ, Biswas S. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus. Drug Resist Updat 2011; 14:45-51.
60. Galdiero S, Falanga A, Tarallo R, et al. Peptide inhibitors against herpes simplex virus infections. J Pept Sci 2013; 19:148-158.
61. Antoine TE, Park PJ, Shukla D. Glycoprotein targeted therapeutics: a newera of antiherpes simplex virus-1 therapeutics. Rev Med Virol 2013; 23:194-208.
62. Krawczyk A, Arndt MA, Grosse-Hovest L, et al. Overcoming drug-resistant herpes simplex virus (HSV) infection by a humanized antibody. Proc Natl Acad Sci U S A 2013; 110:6760-6765.